Which direction aims to reduce negative consequences of substance use by expanding safer, evidence-based options for people who use substances?

Which direction aims to reduce negative consequences of substance use by expanding safer, evidence-based options for people who use substances?

• A. Personalized Medicine With Genetics And Biomarkers
• B. Digital Health Interventions
• C. New Pharmacotherapies Targeting Craving
• D. Expanded Harm-Reduction Approaches

Answer: (D)

Expanding harm-reduction approaches centers on reducing the negative health and social consequences of substance use by broadening access to safer, evidence-based options. This philosophy meets people where they are, rather than insisting on abstinence, and aims to minimize risk while connecting individuals to care when they’re ready. Practical examples include wide naloxone access for overdose reversal, syringe and needle programs, safe consumption spaces where legal, fentanyl test strips, and expanding access to medications for opioid use disorder (like methadone or buprenorphine) within supportive services. When implemented, these strategies have been shown to reduce overdose deaths, lower transmission of infectious diseases, and improve engagement with health care. Other approaches focus on tailoring treatment through genetics, leveraging digital health tools, or developing new medications to reduce cravings. While valuable, they don’t inherently emphasize expanding safer, evidence-based options to the same broad population as harm-reduction strategies do.

Expanding harm-reduction approaches centers on reducing the negative health and social consequences of substance use by broadening access to safer, evidence-based options. This philosophy meets people where they are, rather than insisting on abstinence, and aims to minimize risk while connecting individuals to care when they’re ready. Practical examples include wide naloxone access for overdose reversal, syringe and needle programs, safe consumption spaces where legal, fentanyl test strips, and expanding access to medications for opioid use disorder (like methadone or buprenorphine) within supportive services. When implemented, these strategies have been shown to reduce overdose deaths, lower transmission of infectious diseases, and improve engagement with health care.

Other approaches focus on tailoring treatment through genetics, leveraging digital health tools, or developing new medications to reduce cravings. While valuable, they don’t inherently emphasize expanding safer, evidence-based options to the same broad population as harm-reduction strategies do.